canertinib dihydrochloride has been researched along with alvocidib in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (alvocidib) | Trials (alvocidib) | Recent Studies (post-2010) (alvocidib) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 627 | 66 | 204 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | alvocidib (IC50) |
|---|---|---|---|
| Chain A, Protein (glycogen Phosphorylase) | Oryctolagus cuniculus (rabbit) | 1 | |
| Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.36 | |
| [Tau protein] kinase | Sus scrofa (pig) | 0.36 | |
| Cyclin-T1 | Homo sapiens (human) | 0.0243 | |
| Cyclin-K | Homo sapiens (human) | 1.37 | |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | 8 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.1571 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.36 | |
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | 1.2 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 7.6 | |
| Vitamin K-dependent protein C | Homo sapiens (human) | 0.1429 | |
| Protein kinase C gamma type | Homo sapiens (human) | 8 | |
| Protein kinase C beta type | Homo sapiens (human) | 8 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.1159 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.1589 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.1464 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.2067 | |
| Protein kinase C alpha type | Homo sapiens (human) | 6.2667 | |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.185 | |
| Cyclin-A2 | Homo sapiens (human) | 0.3441 | |
| Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 1.3 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.1837 | |
| Protein kinase C eta type | Homo sapiens (human) | 8 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.2249 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.2367 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.1 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.1983 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4 | |
| Protein kinase C iota type | Homo sapiens (human) | 8 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.525 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.6517 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.3365 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0209 | |
| Cyclin-H | Homo sapiens (human) | 0.3413 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.514 | |
| Cyclin-A1 | Homo sapiens (human) | 0.785 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.1572 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1747 | |
| Cyclin homolog | Herpesvirus saimiri (strain 11) | 0.185 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 5.4933 | |
| Protein kinase C theta type | Homo sapiens (human) | 8 | |
| Protein kinase C zeta type | Homo sapiens (human) | 8 | |
| Protein kinase C delta type | Homo sapiens (human) | 5.63 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1765 | |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | 8 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | 0.3 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.1571 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.2067 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 1.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and alvocidib
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |